Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125957 · ClinicalTrials.gov registry record · Phase 3
The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
A Phase 3 study of Depression and Major Depressive Disorder, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00125957 is a Phase 3 study of Depression and Major Depressive Disorder that has completed, run by Mclean Hospital. The registered enrollment target is 32 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00125957, a Phase 3 study of Depression and Major Depressive Disorder, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant (SSRI) and feel 'better'. Although many people feel 'better', they do not feel completely 'well'. Often, individuals continue to complain of cognitive problems such as lack of attention, diminished motivation, and impaired problem-solving. This study looks at whether residual and cognitive symptoms of depression in individuals are affected by the addition of Wellbutrin (bupropion).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Wellbutrin
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125957
The ClinicalTrials.gov registry entry for NCT00125957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00125957 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00125957 about?
NCT00125957 is a clinical study titled "The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression". Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant (SSRI) and feel 'better'. Although many people feel 'better', they do not feel completely 'well'. Often, individuals continue to complain of cognitive problems such as lack of attention, diminished m...
What is the current status of trial NCT00125957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2005-08. Estimated completion is 2011-12.
What conditions does trial NCT00125957 study?
This clinical trial studies the following conditions: Depression, Major Depressive Disorder, Unipolar Depression.
What interventions are being tested in trial NCT00125957?
The interventions under investigation include: Placebo (DRUG), Wellbutrin (DRUG).
Who is sponsoring clinical trial NCT00125957?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00125957 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.